Skip to content
10-Q

Quarterly Report

ALZAMEND NEURO, INC. ALZN

0001214659-25-004123

← back to feed
Filed
Mar 10, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Mar 7, 2025 6.6M sh
Cash And Equivalents Q3 2024 · Jan 31, 2025 $3.36M
Cash And Equivalents Q3 2024 · Apr 30, 2024 $376.05K
Total Liabilities Q3 2024 · Jan 31, 2025 $725.85K
Total Liabilities Q3 2024 · Apr 30, 2024 $3.23M
Current Assets Q3 2024 · Jan 31, 2025 $3.95M
Current Assets Q3 2024 · Apr 30, 2024 $455.24K
Total Assets Q3 2024 · Jan 31, 2025 $4.18M
Total Assets Q3 2024 · Apr 30, 2024 $631.59K
Shares Diluted restated Q3 2024 · Jan 31, 2024 705.43K sh
Shares Diluted restated Q3 2024 · Jan 31, 2024 672.69K sh
Operating Cash Flow Q3 2024 · Jan 31, 2024 −$6.84M
Eps Diluted restated Q3 2024 · Jan 31, 2024 −$3.77
Eps Diluted restated Q3 2024 · Jan 31, 2024 −$13.52
Eps Basic restated Q3 2024 · Jan 31, 2024 −$3.77
Eps Basic restated Q3 2024 · Jan 31, 2024 −$13.52
Sga Expense Q3 2024 · Jan 31, 2024 $751.17K
Sga Expense Q3 2024 · Jan 31, 2024 $2.82M
Rd Expense Q3 2024 · Jan 31, 2024 $1.91M
Rd Expense Q3 2024 · Jan 31, 2024 $6.27M
Net Income Q3 2024 · Jan 31, 2024 −$2.66M
Net Income Q3 2024 · Jan 31, 2024 −$9.1M
Operating Income Q3 2024 · Jan 31, 2024 −$2.66M
Operating Income Q3 2024 · Jan 31, 2024 −$9.09M